Neuland Laboratories Partners with LIR Life Sciences to Develop Transdermal GLP-1 Obesity Treatment
核心洞察
Neuland Laboratories has entered a development partnership with LIR Life Sciences (搜索) to advance cell-penetrating peptide (搜索) technology for transdermal GLP-1 (搜索)/GIP (搜索) obesity (搜索) therapies.
The collaboration will support pharmacokinetic and pharmacodynamic studies as well as Phase I formulations for LIR Life's patch-based delivery system.
This represents a potentially significant innovation as there are currently no approved transdermal GLP-1 (搜索) therapies on the market.
Neuland Laboratories, a global contract development and manufacturing organisation (CDMO) specialising in complex APIs, has entered into a development partnership with LIR Life Sciences (搜索) Corp, a Canada-based biotechnology company focused on scalable and accessible obesity (搜索) treatments. The collaboration aims to advance LIR Life's cell-penetrating peptide (搜索) (CPP) platform for transdermal GLP-1 (搜索) therapies.
Novel Transdermal Delivery Platform
As part of this engagement, Neuland will develop, test, and manufacture CPPs to support pharmacokinetic (PK) and pharmacodynamic (PD) studies, as well as Phase I formulations for LIR Life's transdermal GLP-1 (搜索)/GIP (搜索) programme. The collaboration is structured to support early-stage development, with potential for expansion into later-phase clinical and commercial manufacturing, subject to successful milestone progression.
LIR Life is developing a patch-based, transdermal delivery system for GLP-1 (搜索) therapies targeting obesity (搜索). Unlike traditional injectable formulations, the platform is designed to enable non-invasive administration, with the potential to improve patient adherence and broaden access. Currently, there are no approved transdermal GLP-1 therapies, positioning this approach as a potentially significant innovation in the treatment landscape.
Strategic Partnership Benefits
For Neuland, the partnership highlights its expanding capabilities in peptide development and manufacturing, particularly in complex and emerging modalities such as CPP-enabled delivery systems. The company supports peptide programmes from early development through commercial scale, with integrated capabilities spanning process development, scale-up, and cGMP manufacturing.
"We are excited to engage Neuland's expertise in peptide development and manufacturing at both small and large scale," said Edward Mills, CEO of LIR Life Sciences (搜索). "This partnership enables us to advance our CPP platform with the precision and consistency required for early-stage development."
Infrastructure Investment
The collaboration builds on Neuland's recent investments in peptide infrastructure, including a new $20 million process development laboratory and a multi-phase commercial peptide manufacturing facility at its Bonthapally campus in Hyderabad. Module one of the peptide facility, representing an investment of approximately $30 million and 6,370 litres of capacity, is expected to become operational by mid-2026.
"This collaboration reflects the rapidly rising demand we see for CDMO's that can advance complex peptide targets, particularly as new delivery technologies emerge," said Saharsh Davuluri, CEO of Neuland Laboratories. "LIR Life's transdermal approach represents a novel application of GLP-1 (搜索) therapies, and we look forward to supporting the development of their CPP platform through our integrated peptide capabilities."
Market Positioning
LIR Life Sciences (搜索) is focused on researching and developing scalable and affordable treatments for obesity (搜索) using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1 (搜索), a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs, with the goal of improving access, adherence, and cost-efficiency in both developed and emerging markets.